Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
18 mars 2021 16h15 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
17 nov. 2020 16h27 HE
|
Idera Pharmaceuticals, Inc.
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE...